



## Press Release

# **Lobe Sciences Ltd. Announces Dr. Herman Williams as Chief Executive Officer of *Altemia*, Inc.**

---

- *Altemia*, Inc. is a wholly owned U.S. subsidiary of Lobe Sciences Ltd.
- Dr. Herman Williams has been appointed as the Chief Executive Officer of *Altemia*, Inc.
- *Altemia*® is a medical food designed to treat deficiencies created by an inborn error of metabolism reported in patients with Sickle Cell Disease
- *Altemia*® will be launched in 2025 for use under the supervision of physicians who treat this genetic disorder

**March 17, 2025**

**VANCOUVER, B.C. -- Lobe Sciences Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), (FWB: LOBE.F),** a commercial stage biopharmaceutical company focused on developing products to treat unmet medical needs, today announced the appointment of Dr. Herman Williams as the Chief Executive Officer of *Altemia*, Inc.

*Altemia*, Inc. is a wholly owned subsidiary of Lobe Sciences which is commercializing a unique medical food product to address the dietary needs of patients suffering from Sickle Cell Disease. Dr. Williams will be leading the launch of *Altemia*®, in 2025 into select communities under the direct supervision of physicians who treat this genetic disorder.

Dr. Williams is a highly seasoned healthcare executive with extensive experience including senior roles with large-scale hospitals and clinics, as Chief Clinical Officer for several companies, and as a founder of HW Healthcare Solutions in 2022. Dr. Williams is a recipient of numerous prestigious awards, including this past month the American Heart Association's William T. Coakley award for his relentless commitment to its mission. Dr. Williams holds a Doctor of Medicine degree from Boston University School of Medicine, a Master's of Business Administration from the University of Washington, and a Master's in Public Health from Harvard University.

"We are very excited that Dr. Williams is bringing his significant experience and commitment to the Lobe Sciences executive team. We are looking forward to the successful launch of *Altemia*® Medical Food to support patients with Sickle Cell Disease" said Dr. Harry Jacobson, Chairman of *Altemia*, Inc.

## **About Lobe Sciences Ltd.**

Lobe Sciences Ltd. is a biopharmaceutical company focused on developing innovative treatments for orphan and rare diseases. The company is advancing proprietary product candidates L-130 for targeting neurological conditions such as Chronic Cluster Headache (CCH) and S-100 for Sickle Cell Disease (SCD). Lobe Sciences also commercializes *Altemia*® MF, a medical food designed to manage deficiencies commonly found in Sickle Cell Disease (SCD).

## **About Altemia, Inc.**

*Altemia*, Inc. is a wholly owned subsidiary of Lobe Sciences that specializes in addressing the dietary needs of individuals with Sickle Cell Disease (SCD). The company's primary product, *Altemia*® MF, is a patent-pending oral emulsion comprised of a proprietary blend of polyunsaturated fatty acid triglyceride esters.

### **For further information:**

**Dr. Fred D. Sancilio, CEO**

**Lobe Sciences Ltd.**

Investor and Media

[Info@Lobesciences.com](mailto:Info@Lobesciences.com)

Phone: +1 (949) 505-5623

[www.lobesciences.com](http://www.lobesciences.com)

### *Forward-Looking Statements*

*This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. These statements, other than those of historical fact, reflect the Company's current expectations and projections about future events and are identified by words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "continue", or their negatives or similar expressions. Such forward-looking statements include, but are not limited to, the Company's plans to enroll patients across clinical sites in the United States and Europe; the potential reduction in drug development timelines afforded by its SPA program; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders.*

*These statements are based on reasonable assumptions and estimates made by the Company's management at the time they were made. However, forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results,*

*performance, or achievements to differ materially from those expressed or implied in such statements. These factors include, but are not limited to, the implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social, and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates, available under the Company's profile on [www.sedarplus.ca](http://www.sedarplus.ca).*

*Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.*

*Furthermore, the Company makes no medical, treatment, or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory authorities have not evaluated claims regarding psilocin. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin can diagnose, treat, cure, or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.*

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.**